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Enterococcus faecium has recently emerged as an important cause of nosocomial infections. We previously
identified 15 predicted surface proteins with characteristics of MSCRAMMs and/or pili and demonstrated that
their genes were frequently present in 30 clinical E. faecium isolates studied; one of these, acm, has been studied
in further detail. To determine the prevalence of the other 14 genes among various E. faecium populations, we
have now assessed 433 E. faecium isolates, including 264 isolates from human clinical infections, 69 isolates
from stools of hospitalized patients, 70 isolates from stools of community volunteers, and 30 isolates from
animal-related sources. A variable distribution of the 14 genes was detected, with their presence ranging from
51% to 98% of isolates. While 81% of clinical isolates carried 13 or 14 of the 14 genes tested, none of the
community group isolates and only 13% of animal isolates carried 13 or 14 genes. The presence of these genes
was most frequent in endocarditis isolates, with 11 genes present in all isolates, followed by isolates from other
clinical sources. The number of genes significantly associated with clinical versus fecal or animal origin (P 
0.04 to <0.0001) varied from 10 to 13, depending on whether comparisons were made against individual clinical
subgroups (endocarditis, blood, and other clinical isolates) or against all clinical isolates combined as one
group. The strong association of these genes with clinical isolates raises the possibility that their preservation/
acquisition has favored the adaptation of E. faecium to nosocomial environments and/or patients.
Enterococci, commensal members of the intestinal flora in
humans and animals, have emerged over the last 3 decades as
important hospital-associated opportunistic pathogens causing
a variety of infections, including urinary tract infections, sur-
gical site infections, bacteremia, and infective endocarditis (20,
21). Several species of enterococci have been recognized, but
more than 90% of infections are caused by only two species,
Enterococcus faecalis and Enterococcus faecium. Until the
1990s, infections due to E. faecalis were reported to outnumber
those due to E. faecium by 9 to 1, but more recently, the
incidence of E. faecium has increased dramatically, and it has
been found as the causative organism in 20 to 36% of entero-
coccal infections in some U.S. hospitals (8, 14, 25, 33). Simi-
larly, hospital-associated E. faecium infections also appear to
be an emerging phenomenon in some European countries
(32). Coinciding with this trend, treatment of E. faecium infec-
tions has increasingly been hampered by the spread of strains
resistant to aminoglycosides, -lactams, and glycopeptides, the
three major classes of drugs of therapeutic choice. Lately, E.
faecium strains resistant to other classes of newly developed
antibiotics have also emerged (17), narrowing available thera-
peutic options.
We and others recently analyzed the genome sequence of
endocarditis-derived E. faecium strain TX0016 and identified
22 genes, named fms (E. faecium surface protein-encoding)
genes, predicted to encode LPXTG family cell wall-anchored
surface proteins (13, 28). We subsequently identified 15 of the
22 genes, including acm (fms8), a previously described gene
encoding a collagen adhesin, as harboring characteristic fea-
tures of MSCRAMMs and/or pili, such as predicted structural
organization into modules with immunoglobulin-like folding,
and demonstrated that all 15 genes occurred frequently among
30 clinically derived E. faecium isolates studied (24, 28). Using
a larger collection of diverse E. faecium isolates, we detected
production of Acm predominantly in isolates derived from
clinical sources (23), despite the gene being present in almost
all isolates. Furthermore, deletion of acm resulted in signifi-
cant attenuation in an experimental endocarditis model (22),
indicating involvement in E. faecium pathogenesis. Another
MSCRAMM-encoding gene that we have characterized, fms10
(subsequently renamed scm), encodes a second collagen-bind-
ing MSCRAMM in E. faecium. Recombinant Scm differs from
Acm in collagen type specificity by showing affinity for collagen
type V instead of types I and IV, which are specifically bound
by Acm. Eleven of the remaining 13 genes were found to be
clustered into four separate genomic loci, each with an adja-
cent class C sortase gene characteristic of pilus-encoding genes
of gram-positive bacteria, and were predicted to form four
distinct pili (28). One of these clusters, E. faecium ebpABC
(ebpABCfm), is transcribed as a single operon, and we demon-
strated polymerization of its predicted major pilus subunit
protein, EbpCfm, into a high-molecular-weight complex (28). A
recent study by Hendrickx et al. showed that antibodies against
EbpCfm (also referred to as PilB) and Fms21 (also referred to
as PilA) stained pili on the surface of E. faecium (12).
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Gene association studies have suggested that acquisition of
resistance determinants to antibiotics, in particular to ampicil-
lin and subsequently vancomycin, as well as acquisition of
other traits, such as a functional acm gene, espEfm (encoding an
enterococcal surface protein), and hylEfm (hyaluronidase-like
gene), may have facilitated colonization, infection, and/or
transmission, although the order of these events cannot cur-
rently be determined (16, 23, 26). Hendrickx and colleagues
recently demonstrated enrichment of 5 of 22 genes encoding
cell wall-anchored proteins in a major hospital-associated
genogroup, designated clonal complex 17 (CC17) (16, 34), in a
study of 131 E. faecium isolates (12, 13). Hence, it is reasonable
to hypothesize that some of the 14 MSCRAMM- and/or pilus-
encoding genes (in addition to acm) may also contribute to
pathogenesis and/or provide E. faecium with a selective advan-
tage in hospital settings, for example, by conferring adherence
properties on host tissues. Enrichment of these traits may also
have contributed to the recent nosocomial success of CC17.
In the present study, we tested a large collection of E. fae-
cium isolates to assess the global distribution of the recently
identified 14 MSCRAMM- and/or pilus-encoding genes in var-
ious clinical and natural populations of E. faecium. The gene
distribution and association of the isolates with a clinical or
nonclinical origin were also analyzed.
MATERIALS AND METHODS
Bacterial isolates, species identification, and growth conditions. A total of 433
clinical and nonclinical E. faecium isolates were included in this study. These
isolates were collected between 1973 and 2005 from diverse geographic locations
(the United States, Argentina, Brazil, France, Belgium, Poland, The Nether-
lands, Spain, Norway, and China), including epidemic and outbreak strains from
around the world (1, 2, 4, 6, 7, 9–11, 15, 18, 19, 23, 26, 27, 29, 31). Isolates known
to be identical by pulsed-field gel electrophoresis to other isolates in this collec-
tion were excluded. The E. faecium isolates were divided into different groups
based on their source of isolation. Among the 264 human clinical isolates (clin-
ical group), 15 were derived from blood cultures of endocarditis patients (endo-
carditis subgroup) and 57 were from blood cultures of nonendocarditis patients
(blood subgroup). The remaining 192 E. faecium clinical isolates, which were
collected from specimens of bile, bone, catheters, cervix, cerebrospinal fluid,
placenta, peritoneal fluid, sputum, urine, and wounds, were grouped as other
clinical isolates (OCI subgroup). Sources of nonclinical isolates included stools of
hospitalized patients (n  69; hospital stool group) and community volunteers
(n 70; community stool group) and animals or animal products (n 30; animal
group). Forty-three of these isolates were previously studied by multilocus se-
quence typing and/or pulsed-field gel electrophoresis and assessed for the pres-
ence of the purK1 allele (a marker for CC17), resulting in 26 being identified as
belonging to CC17 and 17 being identified as non-CC17 isolates (23).
All of the E. faecium isolates, initially identified to the species level by bio-
chemical tests, were confirmed by high-stringency colony hybridization using
intragenic efafm and aac(6)-Ii probes, as previously described (9, 29). The E.
faecium isolates were grown on brain heart infusion (Difco Laboratories, Detroit,
MI) broth/agar and incubated overnight at 37°C.
MSCRAMM- and/or pilus-encoding DNA probes. Genomic DNA of the se-
quenced E. faecium strain TX0016 was extracted using a DNeasy blood and
tissue kit (Qiagen Inc., Valencia, CA); this DNA was used for PCR amplification
of intragenic regions of the 14 MSCRAMM- and/or pilus-encoding genes, using
primers listed elsewhere (28). Radiolabeled DNA probes were prepared from
the purified PCR products with the RadPrime DNA labeling system (Invitrogen,
Carlsbad, CA) according to the protocol supplied by the manufacturer. Unin-
corporated labeled nucleotides were removed using Micro Bio-Spin P-30 col-
umns (Bio-Rad, Hercules, CA).
Colony hybridization. Colony lysate membrane preparation and hybridization
conditions for enterococci were described in our previous studies (5, 29). In brief,
E. faecium isolates were inoculated onto sterile nylon membranes (GE Health-
care, Piscataway, NJ) placed on brain heart infusion agar plates. The sequenced
strain E. faecium TX0016 was included as a positive control. After overnight
growth at 37°C, colonies were lysed on the membrane after treatment with
lysozyme (10 mg/ml) and mutanolysin (4 units/ml). Genomic DNA on the mem-
brane was then denatured, washed, and fixed. Hybridizations were carried out
under high-stringency conditions (hybridization buffer containing 50% formamide,
5 Denhardt’s solution, 5 SSC [1 SSC is 0.15 M NaCl plus 0.015 M sodium
citrate, pH 7.2], 0.1% sodium dodecyl sulfate [SDS], and 100 g/ml calf thymus
DNA) at 42°C overnight, followed by three washes with 2 SSC and 0.1% SDS
at room temperature (15 min each) and two washes with 0.1 SSC and 0.1%
SDS at 50°C (15 min each).
Statistical analysis. The distributions of the 14 MSCRAMM- and/or pilus-
encoding genes in E. faecium isolates originating from different clinical or non-
clinical groups/subgroups were compared using two-tailed Fisher’s exact test. P
values of 0.05 were considered statistically significant.
RESULTS
Overall distribution of predicted MSCRAMM- and/or pilus-
encoding genes in E. faecium isolates. We and others have
shown that acm is present in 99% of isolates of diverse
origins (3, 23). The occurrence of the remaining 14
MSCRAMM- and/or pilus-encoding genes among 264 human
clinical isolates, 69 stool isolates from hospitalized patients, 70
stool isolates from community volunteers, and 30 animal-de-
rived isolates, collected over a period of 33 years from four
continents, is summarized in Table 1. Among all isolates, the
percentages of isolates showing hybridization to the individual
gene probes ranged from 51% to 98%, but there was substan-
tial variation between different groups, ranging from 67%
(fms18) to 99% (fms13) in the clinical group, from 38%
(fms18) to 99% (fms13) in the hospitalized patient-derived
stool isolate group, from 7% (fms18) to 94% (fms17) in the
community volunteer-derived stool isolate group, and from
33% (fms15) to 100% (fms13) in the animal group. The highest
frequency of these genes was detected in the endocarditis sub-
group, with 11 of the genes being carried by 100% of the
isolates. The remaining three genes (fms18, fms20, and fms21)
were found in 53%, 80%, and 93% of endocarditis isolates,
respectively (Table 1).
When total numbers of genes were compared between isolates,
there were 3,372 genes present of 3,696 possible (91%) among the
264 clinical isolates, 709 genes present of 966 possible (73%)
among the 69 stool isolates from hospitalized patients, 597 genes
present of 980 possible (61%) among the 70 stool isolates from
community volunteers, and 274 genes present of 420 possible
(65%) among the 30 isolates from animal or animal products.
Pairwise comparisons of these results showed a highly significant
difference between the clinical group and each of the three non-
clinical groups (P  0.0001; Fisher’s exact test).
Distributions of different combinations of the 14 genes. As
shown in Fig. 1, larger numbers of the MSCRAMM- and/or
pilus-encoding genes were found in clinical than in nonclinical
isolates. As anticipated, stool isolates from hospitalized pa-
tients were found to carry a smaller number of the 14 genes
than isolates from the clinical group but a larger number than
isolates from the two nonclinical groups; this was likely due to
fecal samples from hospitalized patients consisting of a mixture
of both nosocomially derived and community-derived organ-
isms.
Further examination of the hybridization profiles showed
that the presence/absence of the 14 fms genes resulted in 82
observed gene combinations among the 433 isolates. The three
most common combinations accounted for 57% of all isolates.
More specifically, over one-half of the isolates either had all 14
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genes present (28%) or were missing just fms18 (15%) or
fms20 (14%). The remaining combinations were more evenly
distributed among different isolates. The clinical subgroups
contained most of the isolates carrying all or 13 of the genes
(81% of clinical isolates), whereas such isolates were not found
in the community stool group and were relatively rarely found
(13%) in the animal group (Table 2). Furthermore, over two-
thirds (70%) of the community stool isolates carried only 8 to
11 of the 14 genes studied.
Comparison of the distribution of each MSCRAMM- and/or
pilus-encoding gene in infection-derived E. faecium isolates
versus that in community isolates or animal isolates. (i) Dis-
tribution of the 11 MSCRAMM- and/or pilus-encoding genes
clustered at four different genomic loci of TX0016. (a) ebpfm
operon genes. The ebpAfm, ebpBfm, and ebpCfm (pilB) genes
TABLE 1. Distribution of 14 predicted MSCRAMM- and/or pilus-encoding genes among 433 temporally and geographically diverse E. faecium isolates
Gene
% of isolates with gene
Endocarditis
(n  15)
Blood
(n  57)
OCIa
(n  192)
Total clinical
(n  264)
Stool (hospital)
(n  69)
Stool (community)
(n  70)
Animal
(n  30)
Total
(n  433)
scm 100 96 97 97 80 46b 93 86
fms15 100 100 97 98 78 29b 33b 79
fms18 53 77 65 67 38 7b 37c 51
ebp operon genes
ebpAfm 100 96 96 96 72 73
b 77c 87
ebpBfm 100 96 96 96 72 73
b 77c 87
ebpCfm (pilB) 100 96 96 96 72 73
b 77c 87
fms11-fms19-fms16 cluster
fms11 100 96 90 92 68 43b 47b 77
fms19 100 96 90 92 68 43b 47b 77
fms16 100 96 90 92 68 43b 47b 77
fms14-fms17-fms13 clustere
fms14 100 96 96 97 77 87c 73b 90
fms17 100 96 96 97 86 94 77c 93
fms13 100 100 98 99 99 93c 100 98
fms21-fms20 clusterd
fms21 (pilA) 93 95 89 91 88 79c 80 88
fms20 80 79 64 68 61 71 50 66
a Other clinical isolates from various tissues/infections (see Materials and Methods).
b P  0.05 against each of the three clinical subgroups (endocarditis, blood, and OCI groups).
c P  0.05 against the combined clinical group (total).
d Genes in these clusters did not coexist in some of the isolates.
FIG. 1. Percentages of isolates in different clinical and nonclinical
groups that were positive for one or more of the 14 fms genes.
TABLE 2. Distribution of E. faecium isolates based on the number
of genes present
No. of genes
present
% of isolates
Clinical
(n  264)
Stool
(hospital)
(n  69)
Stool
(community)
(n  70)
Animal
(n  30)
Total
(n  433)
14 40 25 0 0 28
13 41 22 0 13 30
12 6 0 6 20 6
11 3 7 17 7 6
10 3 9 16 7 6
9 1 3 10 7 3
8 2 13 27 13 9
7 2 3 4 10 3
6 2 1 9 13 4
5 0.4 6 7 3 3
4 0 10 1 7 2
3 0 1 3 0 1
2 0 0 0 0 0
1 0 0 0 0 0
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were found to coexist, consistent with our previous demonstra-
tion of transcriptional expression of this gene cluster as a single
operon (Table 1) (28). The ebpABCfm operon was found in all
but a few clinical isolates (96 to 100%) but was less frequently
(73 to 77%) found in nonclinical isolates (community and
animal isolates). There was a significant difference for each of
the three clinical subgroups versus the community fecal group
(P  0.019 to 0.0001) and for the blood and OCI subgroups
versus animal group isolates (P  0.0070 and 0.0012, respec-
tively).
(b) fms11-fms19-fms16 cluster. Similar to the ebpABCfm
operon and in agreement with our earlier genome analysis
predicting the organization of the fms11-fms19-fms16 cluster as
an operon, all three genes were carried by each of the isolates
that was positive for any one of the genes (Table 1). These
three genes were present in most isolates of the three clinical
subgroups (ranging from 90 to 100%) but were less common
among community (43%) and animal (47%) isolates, present-
ing a highly significant statistical difference when each of the
clinical subgroups was compared against either the community
or animal isolates (P  0.0002 to 0.0001).
(c) fms14-fms17-fms13 cluster. Although the majority of iso-
lates in all groups carried the fms14-fms17-fms13 cluster (Table
1) (96% of clinical isolates, 83% of community stool isolates,
and 73% of animal isolates), there was still a significant differ-
ence between two of the clinical subgroups (blood isolates and
OCI) and the community stool or animal group (P  0.0002 to
0.038). However, although analysis of the TX0016 genome
predicted organization of this cluster as a pilus-encoding
operon, 10% (45/433 isolates) of isolates did not hybridize to
one or two of the gene probes of this cluster while hybridizing
to the other probe(s). Most (35 [78%]) of these discordant
isolates were derived from nonclinical sources.
(d) fms21-fms20 cluster. Two other genes were also found in
very close proximity to each other in the genome of TX0016,
namely, fms20 and a major pilus subunit-encoding gene, fms21
(pilA) (12, 13, 28). However, they are separated by a putative
class C sortase gene and another open reading frame that lacks
a cell wall anchoring motif. The majority of all clinical isolates
(91%) carried fms21, while fms20 was less common than fms21
and the second least common gene overall (after fms18); fms20
and fms21 genes coexisted in only 66% of the 433 isolates.
(ii) Distribution of the three fms genes not clustered with
other MSCRAMM- and/or pilus-encoding genes of TX0016.
As shown in Table 1, the nonclustered MSCRAMM-encoding
genes of the sequenced TX0016 genome (scm, fms15, and
fms18) showed various distributions in different groups, albeit
with a considerably higher frequency of each gene in each of
the three clinical subgroups than in the community-derived
stool isolate group. No significant variation between the dif-
ferent clinical subgroups (endocarditis isolates, blood isolates,
and OCI) was observed (Table 1). It is notable that carriage of
fms18 was less frequent in the different groups than that of all
other genes. Although there was a clear-cut association be-
tween the presence of scm and a clinical origin (97% of clinical
isolates versus 46% of community-derived isolates; P 
0.0001), the scm gene was also overrepresented in isolates of
animal origin (93%). In contrast, fms15 and fms18 were de-
tected in a minority of animal isolates, and the difference
between animal isolates and each of the three clinical sub-
groups was highly significant for fms15 (P 0.0001), as was the
difference between animal isolates and both the blood and
OCI subgroups for fms18 (P  0.0004 to 0.004).
Presence of the 14 genes in CC17. We previously analyzed 43
isolates studied here for their ancestral relationships and iden-
tified 26 of them as CC17 isolates and 17 as non-CC17 isolates
(23). Among these, 11 of the 14 genes were present in 100% of
the CC17 isolates, while the remaining three genes, fms18,
fms21, and fms20, were present in 58%, 92%, and 81% of the
CC17 isolates, respectively (Table 3). A widely variable but
generally less frequent occurrence was detected in non-CC17
isolates, ranging from 29% to 100%. Overall, 9 of the 14 genes
showed a significantly higher carriage in CC17 isolates than in
non-CC17 isolates, while no statistically significant enrichment
among CC17 isolates was observed for five of the genes.
DISCUSSION
The ability of bacteria to infect and cause disease is often
dependent on specific genes that distinguish more pathogenic
strains from their less pathogenic relatives. In gram-positive
organisms, such as streptococci and staphylococci, these
virulence-associated determinants include surface-anchored
MSCRAMMs (e.g., collagen binding protein Cna of Staphylococ-
cus aureus), surface pili (e.g., fibronectin-collagen-T antigen-car-
rying pili of Streptococcus pyogenes), secreted proteins or enzymes
(e.g., gelatinase of E. faecalis), genes involved in the synthesis of
toxins (e.g., Panton-Valentine leukocidin genes of S. aureus), and
capsular exopolysaccharides (e.g., the Streptococcus pneumoniae
capsule). Recent reports, including one from our laboratory, have
assessed the distribution of newly identified or predicted surface
protein genes, including MSCRAMM- and/or pilus-encoding
genes, in various groups of E. faecium isolates, with each sub-
TABLE 3. Comparison of gene distributions of CC17 and
non-CC17 isolates
Gene
No. (%) of isolates with gene
CC17 (n  26) Non-CC17 (n  17)
scm 26 (100)a 11 (65)
fms15 26 (100)a 5 (29)
fms18 15 (58)a 3 (18)
ebp operon genes
ebpAfm 26 (100)
a 13 (76)
ebpBfm 26 (100)
a 13 (76)
ebpCfm (pilB) 26 (100)
a 13 (76)
fms11-fms19-fms16 cluster
fms11 26 (100)a 5 (29)
fms19 26 (100)a 5 (29)
fms16 26 (100)a 5 (29)
fms14-fms17-fms13 cluster
fms14 26 (100) 15 (88)
fms17 26 (100) 16 (94)
fms13 26 (100) 17 (100)
fms21-fms20 cluster
fms21 (pilA) 24 (92) 15 (88)
fms20 21 (81) 13 (76)
a P  0.05 against non-CC17 isolates in our study.
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group consisting of relatively few isolates that were collected from
various human and animal sources (12, 13, 28). Results from
these studies showed that eight MSCRAMM- and/or pilus-encod-
ing genes (ebpAfm, ebpBfm, ebpCfm, scm, fms13, fms15, fms17, and
fms21) were widely distributed and present in 82 to 94% of iso-
lates; the remaining six genes were found in 26 to 56% isolates,
while acmwas previously shown to be present in99% of isolates
(23).
To determine the presence of these 14 MSCRAMM- and/or
pilus-encoding genes in various E. faecium isolates from clin-
ical and nonclinical environments, we employed an expanded
collection of 433 geographically and temporally diverse E. fae-
cium isolates. Analysis of the total number of these 14 genes in
each group showed a considerably higher carriage rate (91%)
for the clinical group than for the community stool and animal
groups (61% and 65%, respectively), indicating an overall ac-
cumulation and/or higher level of preservation of these genes
in isolates associated with infections in humans. A similar
conclusion can be derived from the hybridization data for 131
isolates recently presented by Hendrickx et al. (12, 13) in which
an estimated 88% of the total number of possible genes were
carried by clinical and hospital outbreak-associated isolates
and 56 to 76% of possible genes were carried by isolates from
other sources. This is in contrast to acm, which was carried by
99% of all isolates, although the Acm protein was expressed
almost exclusively by clinical isolates and was often present as
a pseudogene in nonclinical isolates (23).
Independent analysis of the distribution of each of the genes
studied here also pointed to a strong association with a clinical
source of isolation for three nonclustered genes (scm, fms15,
and fms18) and two of the four pilus-encoding clusters (ebpABCfm
and fms11-19-16). Taken together, these nine genes were
significantly enriched in each of the three clinical subgroups
compared to the community stool group. With the exception
of scm, these genes also occurred significantly more often in
two or more clinical subgroups than in the animal group. When
the clinical subgroups were combined and compared with the
community stool and/or animal group, a significant association
with clinical origin was also observed for four additional genes
(fms14, fms17, fms13, and fms21). Although statistical analyses
confirmed a significant enrichment of these genes in each of
the infection-derived groups (P  0.0001 to 0.019), we ac-
knowledge that it would be an oversimplification to directly
infer function from the presence or absence of a given gene,
particularly since some of the genes may be nonfunctional, as
evidenced by previous findings of acm, fms15, fms16, and fms19
as pseudogenes in some isolates (23, 28). Although direct com-
parisons with the results of Hendrickx et al. (12, 13) are com-
plicated by the lack of information on the presence of each
gene in the different clinical and nonclinical groups, our results
generally agree with these reports, which showed similar en-
richment of these genes. Subsequent assessment of gene dis-
tribution in a subset of our isolates that were previously cate-
gorized as either CC17 or non-CC17 isolates showed more
enrichment in CC17 isolates than that found by Hendrickx et
al. (13), with 11 of the 14 genes present in 100% (26) of CC17
isolates, while the remaining 3 genes were present in 58 to 92%
of CC17 isolates. Furthermore, we detected some genes in
non-CC17 isolates more frequently, e.g., fms14 and fms20,
which were present in 88% and 76% of non-CC17 isolates,
respectively, in our collection, compared to 41% and 42% of
non-CC17 isolates, respectively, in the study of Hendrickx et al.
(13). On the other hand, two of the genes, scm and fms15, were
present at lower rates in non-CC17 isolates (65% and 29%,
respectively) in our study than the previously published rates of
92% and 77% for non-CC17 isolates (13), but this may be a
result of our small non-CC17 isolate sample size.
As shown in Table 1, some of the isolates (mostly from
nonclinical groups) did not hybridize to one or two genes of the
fms14-17-13 cluster, suggesting the possibility of a high recom-
bination rate in this genomic region, which could lead to either
divergent gene sequences or deletion of the genes altogether.
Interestingly, the variation in the fms14-17-13 cluster resulted
mainly from the absence of fms14 and/or fms17 (39/45 iso-
lates), while the putative pilus backbone subunit gene, fms13,
was missing in only 6 of the 45 divergent isolates. Similarly,
fms20 was absent in 25% of isolates positive for the predicted
major pilin gene, fms21, and rarely (0.5% [2/433 isolates])
existed independently. While we were not able to utilize a
low-stringency hybridization approach to detect divergent al-
leles due to apparent cross-reactivity with other pilus-encoding
genes, PCR analyses using multiple intra- and intergenic
primer pairs also failed to amplify these gene fragments from
the selected isolates tested (data not shown). Similar variant
pilus subunit-encoding gene clusters have been reported for
other gram-positive organisms (30).
As expected from the individual gene results, larger numbers
of genes were found to be carried by clinical isolates than by
nonclinical isolates (Fig. 1). Concurrent with this, clinical iso-
lates showed less variability in their gene content, with the
majority of them (80% [212/264 isolates]) exhibiting only three
different gene combinations of the 82 combinations found
among all isolates, while the three most common combinations
for the community stool and animal groups accounted for only
34% (24/70 isolates) and 27% (8/30 isolates) of the isolates,
respectively. Accumulation of these genes in clinical isolates
may be a marker of their clonal origin, a potential factor that
influences the distribution of these genes as well as enrichment
of specific gene combinations. On the other hand, the consid-
erable variability seen in nonclinical isolates, e.g., the presence
of pilus clusters in isolates with otherwise heterogeneous con-
tents of the 14 genes, may have resulted from horizontal gene
transfer between isolates that are not closely related evolution-
arily.
In summary, our observation of the more frequent occur-
rence of many of the MSCRAMM- and pilus-encoding genes
in clinical isolates than in fecal isolates from community vol-
unteers and, generally, animal isolates suggests that their pres-
ervation and/or enrichment may have contributed to the sur-
vival and dissemination of E. faecium in hospital environments.
Our ongoing characterization of these genes aims at revealing
their potential role(s) in E. faecium pathogenesis, such as ad-
herence to host cells and tissues.
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